Navigation Links
Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
Date:3/10/2008

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the company has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) to expand the indication for Zingo to treat the pain associated with peripheral IV insertions and blood draws in adults. Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system is already approved by the FDA to provide local analgesia prior to peripheral IV insertions and blood draws in children three to 18 years of age.

The sNDA submission is based on results of a multi-center, randomized, double-blind study in 699 adult patients, which demonstrated less procedural pain associated with blood draws or IV cannulations in those treated with Zingo compared to placebo. Of the study participants, 348 patients received placebo and 345 received Zingo one to three minutes before undergoing medical procedures requiring venipuncture or IV line placement at the back of hand or antecubital fossa (crux of the elbow). The primary endpoint was pain upon needle insertion, utilizing the VAS pain scale. The mean pain score in the Zingo-treated patients was significantly lower than in the placebo group (p = 0.003).

Demographic characteristics and sites of administration were evenly distributed across treatment groups. Zingo was found to be well tolerated in this patient population. The most common skin assessment findings were redness (erythema), red dots (petechiae) and swelling (edema) at the site of administration. The incidence of adverse events with Zingo was no higher than with placebo.

"The initial commercial thrust for Zingo is in the pediatric setting, where we have focuse
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
2. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
3. Anesiva Appoints Daniel Janney to Board of Directors
4. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
5. Anesiva Announces Completion of Common Stock Offering
6. Anesiva Raises $45 Million in Common Stock Offering
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
9. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
10. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
11. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon is pleased to announce ... session on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical & Scientific Instruments ... and scientific instruments show which will be held at International Conference Hall in ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City ... firms and animal health companies to hear from animal health companies with the ... also received licensing agreements or distribution contracts. This meeting is one of ...
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... 2015 GlassesOff (OTCBB: GLSO), a visual ... the human vision system, announced today a partnership with eight-time ... Chris Paul to develop a new mobile app designed ... their real-life on-court performance. Vision is the inception ... shooting a ball or blocking a pass. The critical impact ...
Breaking Biology Technology:U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ... Parker et al. entitled "Anti-Tumor Activity of Reovirus is ... Irradiation in Primary Patient Glioma Xenografts Resistant to Treatment ... 28th American Society for Virology (ASV) Annual Meeting. The ...
... of 2009 (Excluding Technical, Plastics) at Prior ... - Sales Decline in the Cyclical Segments of Cosmetics and, ... In the first half of 2009, Gerresheimer AG achieved sales at the ... to sales growth for pharmaceutical packaging and systems,with which Gerresheimer today makes ...
... , SAN DIEGO, July 14 Amylin Pharmaceuticals, Inc. ... the second quarter of 2009 on Tuesday, July 21, 2009 at 5:00 p.m. ... lead the call. On the same date post-market, Amylin will release financial results ... The call will be webcast live through Amylin,s corporate Web site ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting 2Gerresheimer Holds its own in Difficult Environment 2Gerresheimer Holds its own in Difficult Environment 3Gerresheimer Holds its own in Difficult Environment 4Amylin Pharmaceuticals to Webcast Second Quarter Results 2
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik ... und findet vom 22. bis 25. Oktober 2015 ... Die Konferenz feiert in diesem ... ist die ICG weltweit zu einem der einflussreichsten ... eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... biochemical variations, or noise, leads to oscillations in gene ... debated for decades the relative importance of nature versus ... and now UCSD scientists report that noise could also ... In a paper in Proceedings of the National Academy ...
... EU-financed sleep research project is coordinated from FinlandIn ... network was establishedto investigate the causes and implications ... as from the social point of view. This ... effects of sleep restriction" will last for four ...
... cells is the work of machines that contain dozens of ... genomes, researchers now have a nearly complete "parts list" of ... all the pieces go. A new study by scientists at ... question for some of the smallest and trickiest components in ...
Cached Biology News:Phenotype is influenced by nature, nurture and noise 2Do the Europeans turn ill sitting up so late? 2Many needles, many haystacks 2
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
Synaptotagmin, phosphoSer309...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Mouse anti-hepatitis delta virus Class: Antibody Product Group: Bacterial and Viral Antigen...
Biology Products: